Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Summary

This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Moderately to Severely Active Crohn Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Abivax S.A.

Last updated on ClinicalTrials.gov

April 27, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites